retatrutide liver nonalcoholic fatty disease nash trial Retatrutide, the triple G, Glucagon-GIP-GLP-1 based triagonist produces substantial resolution of liver fat #NAFLD in PPL with #obesity #ADA2023 @ADA_DiabetesPro @AmDiabetesAssn #NASH trial coming Retatrutide wiped out fat in

I hope you enjoyed this episode

In terms of their effects, Ipamorelin primarily increases bone growth and body weight while Tesamorelin reduces visceral and liver fat, increases muscle area and density and shows beneficial effects on adiponectin and fibrinolytic markers [9, 10, 11, 12, 6, 13]

The additional GIP receptor activation contributes to its overall efficacy profile

Proc Natl Acad Sci USA 1996

However, emerging research has explored potential indirect relationships between GLP-1 receptor agonist therapy and cortisol regulation

(2018) The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma, Oncogene , 37 , 5435-5450, doi: Seibt, T